• Founder(s): Dr. Manfred Gröppel and Dr. Andreas Mühler
  • Established: March 2016
  • CEO(s): Dr. Daniel Vitt
  • Employees: 5
  • Financial Data: Privately funded 
  • Website:


Immunic AG develops immune modulators to block TH17, TH1-mediated immune drawbacks, and autoimmune responses. Their main goal is to develop these drug candidates to clinical proof of concept.

Development of pharmaceuticals is in the immunology space, in particular for autoimmune diseases such as ulcerative colitis, Crohn’s disease, and psoriasis.

Two programs are in the pipeline for this company: IMU-838 where Phase I has just been completed, and IMU-366, which is in preclinical development.

Being located in the heart of a big biotech cluster like Planegg, where Max-Planck-Institute is a next-door neighbor offers many advantages in terms of networks, administration, and logistics.